Sorafenib is a tyrosine kinase inhibitor (TKI) that impedes tumor angiogenesis by targeting hepatocyte cytokine receptors, vascular endothelial growth factor receptor 2 (VEGFR2), and platelet‐derived growth factor receptor [185]. Here, KDR is linked to neoplasm.